Fate Therapeutics downgraded by Cowen
$FATE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cowen downgraded Fate Therapeutics from Outperform to Market Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/18/2024 | Underperform → Neutral | BofA Securities | |
| 6/17/2024 | $4.00 → $6.00 | Neutral → Overweight | Piper Sandler |
| 3/27/2023 | $6.00 | Equal Weight | Wells Fargo |
| 1/24/2023 | $115.00 → $7.00 | Buy → Neutral | H.C. Wainwright |
| 1/6/2023 | $20.00 → $7.00 | Outperform → Market Perform | BMO Capital Markets |
| 1/6/2023 | $71.00 → $12.00 | Overweight → Neutral | Piper Sandler |
| 1/6/2023 | Outperform → Market Perform | Cowen | |
| 1/6/2023 | $107.00 → $5.30 | Buy → Hold | Stifel |
8-K/A - FATE THERAPEUTICS INC (0001434316) (Filer)
S-8 - FATE THERAPEUTICS INC (0001434316) (Filer)
8-K - FATE THERAPEUTICS INC (0001434316) (Filer)
4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
4 - FATE THERAPEUTICS INC (0001434316) (Issuer)